Stock Analysis

3 Stocks Estimated To Be Undervalued By 37.6% To 45.7%

NasdaqGM:STAA
Source: Shutterstock

As the S&P 500 and Nasdaq Composite recently retreated from record highs, investors are closely watching how strong corporate earnings and economic data balance ongoing concerns about tariffs. In this fluctuating environment, identifying undervalued stocks can be a strategic approach for those looking to capitalize on potential market inefficiencies.

Advertisement

Top 10 Undervalued Stocks Based On Cash Flows In The United States

NameCurrent PriceFair Value (Est)Discount (Est)
Robert Half (RHI)$41.80$82.5949.4%
Repligen (RGEN)$114.80$224.9049%
Hesai Group (HSAI)$20.86$41.0949.2%
Freshpet (FRPT)$68.12$133.2648.9%
Definitive Healthcare (DH)$3.99$7.8048.8%
Carter Bankshares (CARE)$18.10$35.5049%
Camden National (CAC)$42.29$83.8049.5%
Atlantic Union Bankshares (AUB)$32.98$65.4549.6%
ACNB (ACNB)$43.36$85.0349%
Acadia Realty Trust (AKR)$18.61$36.6949.3%

Click here to see the full list of 175 stocks from our Undervalued US Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Clearfield (CLFD)

Overview: Clearfield, Inc. manufactures and sells fiber connectivity products both in the United States and internationally, with a market cap of $595.28 million.

Operations: The company generates revenue primarily from its Clearfield segment, which accounts for $140.25 million, and Nestor Cables, contributing $40.16 million.

Estimated Discount To Fair Value: 41.3%

Clearfield, Inc. is trading significantly below its estimated fair value of US$73.27, with a current price around US$43, suggesting it could be undervalued based on cash flows. Recent earnings show a turnaround from a net loss to a net income of US$1.33 million in Q2 2025, highlighting improving financial health. The company’s addition to multiple Russell Growth Indexes underscores market recognition and potential growth prospects despite slower revenue growth forecasts compared to industry benchmarks.

CLFD Discounted Cash Flow as at Jul 2025
CLFD Discounted Cash Flow as at Jul 2025

STAAR Surgical (STAA)

Overview: STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses and delivery systems for the eye, with a market cap of approximately $859.50 million.

Operations: The company generates revenue primarily from its ophthalmic surgical products, amounting to $279.13 million.

Estimated Discount To Fair Value: 37.6%

STAAR Surgical is trading at US$17.76, well below its estimated fair value of US$28.46, highlighting potential undervaluation based on cash flows. The company anticipates becoming profitable within three years, with revenue growth expected to outpace the broader U.S. market slightly. Despite a recent net loss and low future return on equity forecasts, STAAR's inclusion in several Russell Value Indexes reflects market confidence amid strategic shifts like a new CFO appointment and capital stewardship initiatives.

STAA Discounted Cash Flow as at Jul 2025
STAA Discounted Cash Flow as at Jul 2025

Tenable Holdings (TENB)

Overview: Tenable Holdings, Inc. offers cyber exposure management solutions across various global regions and has a market cap of approximately $4.04 billion.

Operations: The company's revenue is primarily derived from its Security Software & Services segment, totaling $923.20 million.

Estimated Discount To Fair Value: 45.7%

Tenable Holdings is trading at US$33.29, significantly below its estimated fair value of US$61.26, suggesting undervaluation based on cash flows. The company is expected to achieve profitability within three years with above-average market profit growth forecasts. Despite a recent net loss and slower revenue growth compared to the U.S. market, Tenable's strategic leadership changes and share buyback initiatives underscore its commitment to enhancing shareholder value amidst expanding cybersecurity solutions.

TENB Discounted Cash Flow as at Jul 2025
TENB Discounted Cash Flow as at Jul 2025

Where To Now?

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:STAA

STAAR Surgical

Designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.

Flawless balance sheet with reasonable growth potential.

Advertisement